ASCO26: David Reardon, MD, Glioblastoma Vaccine - Quiz - MDSpire

ASCO26: David Reardon, MD, Glioblastoma Vaccine

Dana-Farber Cancer Institute's Dr. David Reardon reports on data showing a phase 1 trial looking at a personalized vaccine plus pembrolizumab sparked tumor-targeting T cells in glioblastoma and was linked to longer survival in immune responders.

  • July 1, 2026

Share

Original Source(s)

ASCO26: David Reardon, MD, Glioblastoma Vaccine

  • July 1, 2026

Related Content

Immunotherapy does not impair ovarian function in a mouse model of breast cancer

The impact of abiraterone and enzalutamide on hypokalemia incidence in patients with prostate cancer: a systematic review and meta-analysis

ASCO26: Alicia Morgans, MD, MPH, ARACOG

Dr. Alicia Morgans of Dana-Farber Cancer Institute reported at #ASCO26 that ARACOG found darolutamide was associated with less decline in cognitive testing than enzalutamide, which may help guide treatment choice.

  • July 1, 2026

  • 1 min